8-K: Champions Oncology Reports Q3 FY26 Results, Service Revenue Up

Champions Oncology announced its third quarter fiscal 2026 financial results, reporting record study service revenue of $16.6 million, up 32% year-over-year, despite a modest decline in total revenue.

Summary

• Total revenue for the third quarter of fiscal 2026 was $16.6 million, a 2.8% decrease from $17.0 million in the prior-year period, primarily due to the absence of a $4.5 million data license transaction recognized in Q3 FY25.
• Excluding the prior-year data license, study service revenue increased by 32% year-over-year to a record $16.6 million, driven by strong study execution and conversion of previously booked work.
• The company reported a GAAP net loss of $279,000 for the quarter, compared to net income of $4.5 million in Q3 FY25.
• Adjusted EBITDA for the quarter was $574,000, a significant decrease from $5.1 million in Q3 FY25.
• Total costs and operating expenses increased by 34.3% to $16.8 million for the quarter, up from $12.5 million in Q3 FY25.
• Oncology services margin for the quarter was 47%, down from 61% in Q3 FY25, attributed to higher outsourced radiolabeling work and the absence of high-margin data revenue.
• For the nine months ended January 31, 2026, total revenue increased 2.2% to $45.6 million, while the company reported a net loss of $508,000 and adjusted EBITDA of $1.5 million.
• Cash on hand at the end of the quarter was approximately $7.1 million, with no debt.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. While core service revenue growth is strong and management maintains a positive full-year outlook, the significant decline in overall revenue and profitability metrics due to a prior-year comparison and increased costs warrants caution.

Positives

• Record study service revenue of $16.6 million, representing a 32% year-over-year increase.
• Achieved third consecutive quarter of positive adjusted EBITDA, totaling $574,000.
• Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the full fiscal year.
• Strong study execution and conversion of previously booked work contributed to robust service revenue.
• Early momentum is being observed in the data business.
• Strategic investments are being made in the data platform and discovery therapeutics initiatives to support future growth.
• Ended the quarter with approximately $7.1 million in cash and no debt.

Negatives

• Total revenue for the quarter decreased by 2.8% year-over-year to $16.6 million, primarily due to the absence of a $4.5 million data license transaction from the prior year.
• Reported a GAAP net loss of $279,000 for the quarter, a significant decline from net income of $4.5 million in the prior-year period.
• Adjusted EBITDA decreased substantially to $574,000 from $5.1 million in the prior-year quarter.
• Oncology services margin declined to 47% from 61% in the prior-year quarter, impacted by higher outsourced radiolabeling costs and the absence of high-margin data revenue.
• Total costs and operating expenses increased by 34.3% to $16.8 million for the quarter, driven by higher outsourced lab services, R&D, sales & marketing, and G&A expenses.
• Net cash used in operating activities was approximately $1.4 million for the quarter and $2.474 million for the nine months ended January 31, 2026.

Risks

• Forward-looking statements inherently involve risks and uncertainties, and actual results could differ materially from anticipated outcomes due to unforeseen factors.
• Quarterly revenue can fluctuate depending on study timing and completion milestones, which may lead to near-term normalization before continued growth.
• Reliance on outsourced lab services, such as radiolabeling, currently impacts cost of sales and margins, though management expects these costs to decline as work transitions in-house over time.

Future Outlook

Champions Oncology remains on track to achieve year-over-year revenue growth and positive adjusted EBITDA for the full fiscal year. Management anticipates that quarterly revenue fluctuations may normalize in the near term before continuing to grow as bookings expand. The company expects margins to improve over time as outsourced radiolabeling work transitions in-house. Continued investment in the data platform, discovery therapeutics initiatives, and the commercial organization is planned to expand opportunities and support future growth, with confidence in long-term growth driven by its differentiated tumor bank and expanding capabilities.

Management Comments

• Robert Brainin, CEO: "We delivered strong operational performance in the third quarter, including another quarter of record study services revenue and our third consecutive quarter of positive adjusted EBITDA."
• Robert Brainin, CEO: "While quarterly results can fluctuate in our business, we remain on track for annual growth and full-year positive adjusted EBIDTA while continuing to invest in our data platform and discovery therapeutics initiatives."
• Robert Brainin, CEO: "We are also encouraged by the early momentum we are beginning to see in our data business and remain confident that our differentiated tumor bank, expanding capabilities, and growing customer engagement position Champions well for long-term growth."
• David Miller, CFO: "Study service revenue grew 32% year over year, benefiting in part from the conversion of previously booked work during the quarter."
• David Miller, CFO: "Total revenue declined modestly compared to the prior-year period due to the absence of the $4.5 million data license transaction recognized in the third quarter of last year."
• David Miller, CFO: "Cost of sales during the quarter included more than $2 million of outsourced radiolabeling work. As this work transitions in-house over time, we expect these costs to decline and margins to improve."
• David Miller, CFO: "We also continue to invest in both our commercial organization and our data platform capabilities to expand our pipeline of opportunities and support future growth."

Industry Context

StockSavvy.ai notes that Champions Oncology operates in the highly competitive and innovation-driven translational oncology research sector. While the company's core study service revenue growth of 32% is robust, the overall revenue decline due to the absence of a prior-year data license highlights the potential volatility from one-off transactions. The strategic investments in data platforms and in-house capabilities align with broader industry trends towards integrated R&D solutions and data-driven drug discovery, aiming to enhance efficiency and capture market share in a growing but cost-sensitive environment.

Comparison to Industry Standards

• The 32% year-over-year growth in study service revenue is strong and suggests effective operational execution in its core business, potentially outperforming some peers in the contract research organization (CRO) space focused on oncology.
• The decline in Adjusted EBITDA and GAAP net income, despite service revenue growth, indicates pressure on profitability, possibly due to increased operational costs and R&D investments, which could be a common challenge for growth-oriented biotech service providers investing heavily in new platforms.
• The oncology services margin of 47% is lower than the prior year's 61%, which could be below the higher end of the industry for specialized preclinical CROs, but the company's plan to bring outsourced work in-house suggests a strategy to improve this metric over time.

Stakeholder Impact

• Shareholders: Positive impact from strong core service revenue growth and positive full-year outlook, but negative impact from current quarter's net loss and reduced Adjusted EBITDA compared to prior year.
• Employees: Potential positive impact from continued investment in commercial organization and R&D, suggesting job stability and growth opportunities.
• Customers: Positive impact from strong study execution, expanding capabilities, and investment in data platforms, leading to enhanced service offerings.
• Creditors: Positive impact from the company having no debt and a reasonable cash position, indicating financial stability.

Next Steps

• Full details of the company's financial results will be available on or before March 16, 2026, in the company's Form 10-Q.
• Transition outsourced radiolabeling work in-house over time to reduce costs and improve margins.
• Continue to invest in the commercial organization and data platform capabilities to expand the pipeline of opportunities and support future growth.
• Advance the company's data licensing platform through greater investment in sequencing and related activities.

Key Dates

Recommendation

The company demonstrates strong operational performance in its core study services, with significant year-over-year growth. However, the overall revenue decline and substantial drop in GAAP net income and Adjusted EBITDA compared to the prior year, largely due to a one-off data license in the comparative period and increased operating costs, present a mixed financial picture. While management's full-year outlook is positive and strategic investments are underway, the current quarter's profitability challenges suggest a 'hold' recommendation. Investors should monitor the execution of cost-saving initiatives and the growth trajectory of the data business to assess future performance.

Keywords

Oncology Research, Translational Oncology, Biopharma Services, Preclinical Research, Patient-Derived Xenograft, PDX Models, Drug Discovery, Cancer Research, Biotechnology, Contract Research Organization, CRO, Data Platform